Educational information, not medical advice — ask your doctor or midwife.
Track Punarnavadi Guggulu with reminders and record whether it helped, in the app.
Punarnavadi Guggulu is a time-honored Ayurvedic compound formula described in classical texts such as the Sharangadhara Samhita. It combines the diuretic and anti-inflammatory properties of Punarnava root with the purifying and anti-inflammatory Guggulu resin, plus a supporting cast of herbs including Triphala, Gokshura, and the three pungents (Trikatu). Together these ingredients are traditionally classified as a formula that reduces 'ama' (metabolic toxins) and excess fluid ('kapha') from tissues.
Punarnava contains punarnavoside and alkaloids like punarnavine that have documented diuretic and anti-inflammatory effects, helping the body shed excess fluid and calm inflamed tissues. Guggulu resin contributes guggulsterones and other bioactive compounds that support joint comfort and healthy inflammatory responses. The Triphala and Trikatu components support digestion and absorption, ensuring the formula works effectively throughout the body.
Classically prepared as hand-rolled vati (pills) using purified Guggulu as the binding base. Modern manufacturers produce them as standardized compressed tablets, typically 250–500 mg each. Powder form is less common but used in some traditional preparations. Tablets and vati are the most practical and widely available forms.
Punarnavadi Guggulu is described in the Sharangadhara Samhita, a 13th–14th century Ayurvedic text, and has been a foundational formula in Ayurvedic clinical practice for managing conditions that correspond roughly to edema, kidney disease, and arthritis. Punarnava literally means 'that which renews' in Sanskrit, reflecting its traditional reputation as a rejuvenating herb for the kidneys and fluid systems.
Evidence grades and traditional-use labels are explained in our methodology. Nothing here is medical advice.
What it is typically used for, usual dose, cautions, and the study behind it where real trial data exists.
One email with the summary. We'll also send a short weekly evidence update — unsubscribe any time.